What’s New in Multiple Myeloma? [Webchat]
…MD, MPP, Clinical Director of the Jerome Lipper Multiple Myeloma Center, discussed the different ways that patients can be treated with multiple myeloma, as well as exciting avenues of treatment,…
…MD, MPP, Clinical Director of the Jerome Lipper Multiple Myeloma Center, discussed the different ways that patients can be treated with multiple myeloma, as well as exciting avenues of treatment,…
…in life. I quickly began an array of treatments at the Jerome Lipper Multiple Myeloma Center at Dana-Farber/Brigham and Women’s Cancer Center for my multiple myeloma, a disease that was…
…required in his last role. In 2014, Horn, then 50, was diagnosed with multiple myeloma—a cancer of plasma cells—after a minor slip at work sent him to the emergency room….
In a surprising rebuttal of previous findings, a new study shows that African Americans with multiple myeloma have an overall higher survival rate than Caucasians with the disease when all…
For many patients with lymphoma or multiple myeloma, a stem cell transplant with their own stem cells (an autologous transplant) or CAR T-cell therapy can extend life significantly or even…
…physical symptoms of myeloma develop. Now, Dana-Farber scientists and an international team of researchers have tracked the genomic changes that occur as smoldering multiple myeloma (SMM) advances to myeloma. Their…
…myeloma is almost always preceded by MGUS, although not every case of MGUS will evolve into multiple myeloma, she explains. Smoldering multiple myeloma, a condition in which there are abnormal…
…and multiple myeloma. “We’re starting to see a lot of hematologic malignancies benefit from immunotherapy,” says Irene Ghobrial, MD. “The excitement is there for so many trials and several new…
…as the new standard for managing myeloma and evaluating myeloma drugs. Nikhil Munshi, MD. “The success of new agents in extending the lives of patients with multiple myeloma has created…
…podcast episode, Irene Ghobrial, MD, and Matthew Davids, MD, of Dana-Farber’s Hematologic Oncology Treatment Center, discuss some of these new treatments and clinical trials for multiple myeloma, leukemia and other…
…and LeBow Institute for Myeloma Therapeutics at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC). Managing Myeloma Multiple myeloma begins with mutations in the development of B cells — white blood cells…
…then 61, was diagnosed with stage III multiple myeloma – and given three years to survive. Several rounds of chemotherapy, two stem cell transplants, and eight years later, Solomon is…
Treatment advances for multiple myeloma continue to bring improved outcomes for patients in different stages of their disease. Recent clinical trial reports show progress in treating two myeloma populations —…
…for multiple myeloma. Path to PROMISE The sisters’ path to PROMISE began in 2016 when Musso was diagnosed with smoldering multiple myeloma (SMM), a condition marked by abnormal proteins known…
…Myeloma Therapeutics and the Jerome Lipper Multiple Myeloma Center. The trial, as reported in mid-2019, showed that isatuximab added to pomalidomide and dexamethasone produced significantly better outcomes than pomalidomide and…
…full medical workup, which led to a diagnosis: multiple myeloma, a blood cancer that was weakening the bone marrow in multiple spots throughout his body including his skull. Since the…
…Science at the Jerome Lipper Multiple Myeloma Center at Dana-Farber. “It provides clues to some of the less understood molecular mechanisms in myeloma and may lead to new therapeutic interventions.”…
…for myself.” Precursor conditions are blood disorders that may evolve into cancers such as leukemia, Waldenström’s macroglobulinemia, and multiple myeloma. They are often asymptomatic and diagnosed incidentally by routine blood…
Earlier this year, a novel drug became the first agent to receive U.S. Food and Drug Administration (FDA) approval for patients with multiple myeloma who have exhausted all types of…
…multiple myeloma at high risk of developing active disease, 71 percent responded to the regimen, and none had developed active myeloma in the course of the study to date. This…